State Street Corp Bio Atla, Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Bio Atla, Inc. stock. As of the latest transaction made, State Street Corp holds 791,278 shares of BCAB stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

791,278

Previous 724,369 9.24%

Holding current value

$1.08 Million

Previous $1.78 Million 52.78%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $125,788 - $231,505	66,909 Added 9.24%	791,278 $2.72 Million
Q3 2023 Nov 14, 2023	BUY	$1.7 - $3.07 $20,570 - $37,147	12,100 Added 1.7%	724,369 $1.23 Million
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $1.64 Million - $2.24 Million	579,063 Added 434.71%	712,269 $2.14 Million
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $31,279 - $112,200	13,600 Added 11.37%	133,206 $356,000
Q4 2022 Feb 14, 2023	BUY	$7.63 - $11.01 $305,200 - $440,400	40,000 Added 50.25%	119,606 $986,000

Q3 2022 Nov 15, 2022	BUY	$2.94 - $11.87 $69,384 - $280,132	23,600 Added 42.14%	79,606 $613,000
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $487,674 - $1.23 Million	-228,955 Reduced 80.35%	56,006 $160,000
Q1 2022 May 16, 2022	SELL	$4.38 - $18.78 $3.69 Million - $15.8 Million	-841,960 Reduced 74.71%	284,961 $1.43 Million
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $3.48 Million - $5.67 Million	183,152 Added 19.41%	1,126,921 $22.1 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $8.72 Million - $13 Million	296,300 Added 45.76%	943,769 $27.8 Million
Q2 2021 Aug 16, 2021	BUY	$38.07 - $56.17 $18.2 Million - $26.8 Million	477,387 Added 280.68%	647,469 $27.4 Million
Q1 2021 May 17, 2021	BUY	$32.41 - $70.91 $5.51 Million - $12.1 Million	170,082 New	170,082 $8.65 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $49.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Bio Atla, Inc. Transaction History